Great research starts with great data.

Learn More
More >
Patent Analysis of

DNA molecule used for recombinant Pichia plasmid and recombinant Pichia strain expressing PprI protein of Deinococcus radiodurans

Updated Time 12 June 2019

Patent Registration Data

Publication Number

US10000761

Application Number

US15/123757

Application Date

30 May 2014

Publication Date

19 June 2018

Current Assignee

SOOCHOW UNIVERSITY

Original Assignee (Applicant)

SOOCHOW UNIVERSITY

International Classification

C12N15/81,C07K14/195,C12N9/52,A61K38/00

Cooperative Classification

C12N15/815,C07K14/195,C12N9/52,A61K38/00

Inventor

YANG, ZHANSHAN,WU, WEI,QIAO, HUIPING,WEN, LING,SHI, YI,REN, LILI,YU, DONG

Patent Images

This patent contains figures and images illustrating the invention and its embodiment.

US10000761 DNA molecule used recombinant 1 US10000761 DNA molecule used recombinant 2 US10000761 DNA molecule used recombinant 3
See all images <>

Abstract

A DNA molecule comprising the sequence set forth in SEQ ID NO: 1, a recombinant Pichia plasmid into which the DNA molecule is inserted, and a recombinant Pichia strain obtained by the transformation of the recombinant Pichia plasmid into a competent Pichia cell and efficiently expressing the PprI protein of Deinococcus radiodurans.

Read more

Claims

1. A DNA molecule comprising the nucleotide sequence set forth in SEQ ID NO: 1.

2. The DNA molecule according to claim 1, wherein the nucleotide sequence set forth in SEQ ID NO: 1 is obtained by overlapping PCR amplification from the primers of the nucleotide sequences set forth in SEQ ID NOs: 2-41.

3. The DNA molecule according to claim 1, wherein it comprises the nucleotide sequence set forth in SEQ ID NO: 1 and a 6× His tag sequence, with the 6× His tag sequence being located at the 5′-end of the nucleotide sequence set forth in SEQ ID NO: 1.

4. A recombinant Pichia plasmid, wherein it is obtained by insertion of a DNA molecule comprising the nucleotide sequence set forth in SEQ ID NO: 1 into a Pichia expression plasmid.

5. The recombinant Pichia plasmid according to claim 4, wherein it is obtained by insertion of a DNA molecule comprising the nucleotide sequence set forth in SEQ ID NO: 1 and a 6× His tag sequence between the CpoI and the NotI cleavage sites in pHBM-905A plasmid, wherein the 6 × His tag sequence is located at the 5′-end of the nucleotide sequence set forth in SEQ ID NO: 1.

6. A recombinant engineered Pichia strain, characterized in that it is obtained by transformation of the recombinant Pichia plasmid according to claim 4 into a competent Pichia cell.

7. The recombinant engineered Pichia strain according to claim 6, characterized in that it is obtained by linearization of the recombinant Pichia plasmid by Sal I cleavage, and then electrotransformation of the linearized plasmid into a competent Pichia GS115 cell.

8. A method for preparing PprI protein, comprising culturing the recombinant engineered Pichia strain according to claim 6, and collecting the culture supernatant containing the Pprl protein.

9. The method according to claim 8, further comprising induction expression of the Pprl protein from the recombinant engineered Pichia strain, and purification of the Pprl protein.

Read more

Claim Tree

  • 1
    1. A DNA molecule comprising
    • the nucleotide sequence set forth in SEQ ID NO: 1.
    • 2. The DNA molecule according to claim 1, wherein
      • the nucleotide sequence set forth in SEQ ID NO: 1 is obtained by overlapping PCR amplification from the primers of the nucleotide sequences set forth in SEQ ID NOs: 2-41.
    • 3. The DNA molecule according to claim 1, wherein
      • it comprises
  • 4
    4. A recombinant Pichia plasmid, wherein
    • it is obtained by insertion of a DNA molecule comprising
    • 5. The recombinant Pichia plasmid according to claim 4, wherein
      • it is obtained by insertion of a DNA molecule comprising
  • 6
    6. A recombinant engineered Pichia strain, characterized in that
    • it is obtained by transformation of the recombinant Pichia plasmid according to claim 4 into a competent Pichia cell.
    • 7. The recombinant engineered Pichia strain according to claim 6, characterized in that
      • it is obtained by linearization of the recombinant Pichia plasmid by Sal I cleavage, and then electrotransformation of the linearized plasmid into a competent Pichia GS115 cell.
  • 8
    8. A method for preparing PprI protein, comprising
    • culturing the recombinant engineered Pichia strain according to claim 6, and collecting the culture supernatant containing the Pprl protein.
    • 9. The method according to claim 8, further comprising
      • induction expression of the Pprl protein from the recombinant engineered Pichia strain, and purification of the Pprl protein.
See all independent claims <>

Description

The present application is a national phase of International Application No. PCT/CN2014/078900, filed on May 30, 2014, which claims the priority of Chinese Patent Application No. 201410153614.3, titled “A DNA MOLECULE, RECOMBINANT PICHIA PLASMID AND RECOMBINANT PICHIA STRAIN EFFICIENTLY EXPRESSING PPRI PROTEIN OF DEINOCOCCUS RADIODURANS” filed with the Patent Office of China on Apr. 16, 2014, the contents of which are incorporated herein by reference in its entirety.

FIELD OF THE INVENTION

The present invention relates to the field of biotechnology, specifically to a DNA molecule, a recombinant Pichia plasmid and a recombinant Pichia strain efficiently expressing PprI protein of Deinococcus radiodurans.

BACKGROUND OF THE INVENTION

In nuclear emergencies such as nuclear accidents, nuclear terrors and nuclear wars, ionizing radiation can cause serious acute radiation injury (ARI) in humans. Treatment and prevention of the radiation-induced injuries concerns peaceful uses of atomic energy and national nuclear safety, and thus studies in this field has become a research field which receives high attention and significant investment from governments and scholars around the world.

Deinococcus radiodurans (DR) is a prokaryotic bacterium having the strongest radioresistance found on the earth to date, and the extremely strong radioresistance of this bacterium is associated with its own perfect and efficient DNA repair system, in which a plurality of DNA repair genes and proteins thereof play a crucial role in its specific radioresistance. In 1999, White et al. have firstly disclosed the gene sequence of DR, wherein an inducer of pleiotropic proteins promoting DNA repair (pprI) is one radioresistant gene having important regulatory effect in the Deinococcus radiodurans. PprI gene contains 987 bp, and encodes 328 amino acids (AAs), and from which the product PprI protein is encoded by DR_0167, with a molecular weight of 37 KD. Recent studies have shown that, pprI gene is the master switch gene for controlling the DNA repair and protection pathways of Deinococcus radiodurans; and after radiation of Deinococcus radiodurans, the PprI protein could up-regulate the expression of over 210 genes via multiple signaling pathways, in which 21 genes associated with DNA repair and replication are included [H Lu, H Chen, G Xu, et al. DNA Repair, 2012, 11(2):139-145]. In the past more than 50 years from the discovery of Deinococcus radiodurans, intensive studies on the function of the genes and proteins of Deinococcus radiodurans as well as the mechanisms thereof have been carried out by scholars around the world. However, to date, these studies only focus on prokaryotic cells, that is, Deinococcus radiodurans itself or Escherichia Coli.

In Chinese patent application No. 200910003512.2, a eukaryotic expression recombinant plasmid pCMV-HA-pprI from Deinococcus radiodurans pprI gene was firstly constructed, which was transformed into a human embryo kidney HEK-293T cell and a radiated mammal to successfully express PprI protein, which has very significant preventive and therapeutic effect on fatal acute radiation injury in animals, suggesting that the PprI protein has potential to become a new biological agent for prevention and treatment of acute radiation injury. However, presently, from the eukaryotic expression recombinant plasmid pCMV-HA-pprI in this patent, it is still difficult to obtain efficiently and massively expressed and purified PprI protein via human cell engineering.

A prokaryotic expression system Escherichia Coli can be used for efficient expression and purification of PprI protein [ZHANG Yongqin, ZHOU Hui, CHEN Jie, YANG Zhanshan, JOURNAL OF RADIATION RESEARCH AND RADIATION PROCESSING, 2011, 29(2): 117-122]; however, such a method have many defects in that: 1. the expressed protein is not subjected to post-translational modification such as glycosylation, resulting in a decreased activity; 2. the expressed protein is present in the form of inclusion body, which also results in a decreased activity of the protein upon extraction through denaturation; 3. there may be endotoxins and toxic proteins from Escherichia Coli itself blended in the protein product of interest, resulting in unexpected toxicity.

Yeast is one of eukaryotic expression systems commonly used in gene engineering, among which Pichia pastoris is one of yeast engineering strains using methanol as the sole carbon source. Such yeast has the following advantages: 1. such yeast is simple in genetic manipulation, has a highly stable genome, and can express an exogenous gene at a high level; 2. such yeast can proceed post-translational modifications of a protein, such as glycosylation, disulfide bond formation, signal peptide cleavage, etc.; 3. the expression vector does not contain a yeast replication origin, the exogenous gene is homologously recombined into the chromosome of a yeast cell and exists stably, and the integrated exogenous gene can passage stably along with the growth of yeast.

If the Deinococcus radiodurans PprI protein can be expressed and purified by the eukaryotic expression system Pichia, the defects of expression and purification of PprI protein with a human cell or a prokaryotic expression system Escherichia Coli in the prior art will be improved or solved. However, Deinococcus radiodurans belongs to prokaryotic organism, which has huge differences in phylogenetic evolution from the eukaryotic organism Pichia, for example, significant differences in gene and protein composition and function, amino acid codon preference of a protein and other aspects. Therefore, if a Deinococcus radiodurans PprI gene is directly constructed into a Pichia expression system via gene engineering, as demonstrated by pre-experimental studies, it is impossible and also is adverse to efficiently express the Deinococcus radiodurans PprI protein, which problem cannot be successfully solved easily in accordance with the general genetic modification techniques in the art.

Therefore, the present invention provides a technology for successful expression and purification of PprI protein of Deinococcus radiodurans R1 via an eukaryotic expression system Pichia, which will establish a solid basis for further studies on functions, mechanisms and applications of this protein, make up for the blank that there has yet been no radioresistant prokaryotic protein drug in the field of treatment and prevention of radiation injury internationally, and rises to the internationally advanced ranks in studies on original protein drugs as radioprotective agents.

SUMMARY OF THE INVENTION

In view of this, an object of the present invention is to provide a new synthesized DNA molecule which enables the DNA molecule to successfully and efficiently express and purify PprI protein via Pichia pastoris.

In addition, the present invention further provides a recombinant plasmid comprising the DNA molecule and a recombinant Pichia strain efficiently expressing the PprI protein of Deinococcus radiodurans, which can also achieve the object of the present invention.

In order to achieve the above objects of the invention, the present invention provides the following technical solutions.

A DNA molecule, which comprises the nucleotide sequence set forth in SEQ ID NO: 1.

In the present invention, the sequence of the Open Reading Frame (ORF) in the pprI gene (DR_0167, Gene ID: 1798483) of Deinococcus radiodurans R1 is optimized and modified to encode and synthesize a new pprI gene, i.e. the nucleotide sequence set forth in SEQ ID NO: 1, which is called “Pi-pprI gene” to be distinguished from the original pprI gene, provided that the amino acid sequence of PprI protein keeps constant.

A DNA molecule comprising the nucleotide sequence set forth in SEQ ID NO: 1, as described herein, means that, in addition to the nucleotide sequence set forth in SEQ ID NO: 1, some sequences such as a 6× His tag sequence for convenient separation and purification of protein can be added. Those skilled in the art are able to connect these sequences which do not affect the normal expression of the Pi-pprI gene with the Pi-pprI gene sequence according to the prior art, which can be achieved for those skilled in the art.

In addition, for those skilled in the art, according to the cleavage site into which a plasmid is to be actually inserted, corresponding cleavage sites can be added at both ends of the DNA molecule, and other suitable tag sequences which are not limited to the 6× His tag sequence as mentioned herein can also be selected. After the present invention provides the sequence of the key Pi-pprI gene, these selections all can be achieved according to the prior art, which similarly does not go beyond the scope of the core technology in the present invention.

Preferably, the nucleotide sequence set forth in SEQ ID NO: 1 is obtained by Overlapping PCR amplification from the primers of nucleotide sequences set forth in SEQ ID NOs: 2-41. In the present invention, the overlapped portions of a series of overlapped 42s (hereinafter abbreviated as p-1 to p-40) of the nucleotide sequences set forth in SEQ ID NOs: 2-41 are complementarily annealed to form a template DNA, then the nucleotide sequence set forth in SEQ ID NO: 1 is synthesized and obtained by Overlapping PCR method. FIG. 1 shows a schematic diagram of Overlapping PCR amplification.

Preferably, by the above preparation method, three fragments are synthesized and obtained with the primers (p-1 to p-16) of the nucleotide sequences set forth in SEQ ID NOs: 2-17, the primers (p-15 to p-28) of the nucleotide sequences set forth in SEQ ID NOs: 16-29 and the primers (p-27 to p-40) of the nucleotide sequences set forth in SEQ ID NOs: 28-41, respectively, and then a full DNA molecule is formed by amplifying with the primer (p-1) of the nucleotide sequence set forth in SEQ ID NO: 2 and the primer (p-40) of the nucleotide sequence set forth in SEQ ID NO: 41.

Preferably, the Overlapping PCR method is performed under the following synthesis conditions: 98° C. for 30 s, 58° C. for 30 s, 72° C. for 1 min, for totally 25 cycles; and finally 72° C. for 7 min. The reaction system is as follows:


p-1 (10 μmol/l)
1
μl
p-n (10 μmol/l)
1
μl
p-2 to p-(n − 1)(1 μmol/l)
each 1.5
μl
5 × PrimeSTAR ® Buffer
10
μl
dNTPs (2.5 mmol/l)
4
μl
PrimeSTAR ® HS DNA Polymerase
0.5
μl
ddH2O
added to a total volume of 50
μl

Preferably, the DNA molecule of the present invention comprises the nucleotide sequence set forth in SEQ ID NO: 1 and a 6× His tag sequence, in which the 6× His tag sequence is located at the 5′-end of the nucleotide sequence set forth in SEQ ID NO: 1, which DNA molecule is prepared according to the following method.

Using a DNA molecule comprising the nucleotide sequence set forth in SEQ ID NO: 1 as the template, PCR amplification is performed using a primer of a nucleotide sequence set forth in SEQ ID NO: 42 bearing a 6× His tag sequence and a primer of a nucleotide sequence set forth in SEQ ID NO: 41, to obtain a DNA molecule comprising the nucleotide sequence set forth in SEQ ID NO: 1 and the 6× His tag sequence.

The PCR amplification is carried out under the following conditions: 95° C. for 5 min; 94° C. for 30 s, 50° C. for 30 s, 72° C. for 90 s, for totally 30 cycles; and finally 72° C. for 10 min, then kept at 4° C.

Meanwhile, the present invention further provides a recombinant Pichia plasmid obtained by insertion of a DNA molecule comprising a nucleotide sequence set forth in SEQ ID NO: 1 into a Pichia expression plasmid.

Preferably, the recombinant Pichia plasmid is obtained by insertion of a DNA molecule comprising a nucleotide sequence set forth in SEQ ID NO: 1 and a 6× His tag sequence between the Cpo I and the Not I cleavage sites in pHBM-905A plasmid, in which the 6× His tag sequence is located at the 5′-end of the nucleotide sequence set forth in SEQ ID NO: 1. A schematic diagram of construction of the recombinant Pichia plasmid of the present invention is shown in FIG. 2.

In addition, the present invention further provides a recombinant engineered Pichia strain obtained by transformation of any one of the recombinant Pichia plasmids of the present invention into a competent Pichia cell.

Preferably, the recombinant engineered Pichia strain is obtained by linearization of the recombinant Pichia plasmid by Sal I cleavage, and then electrotransformation into a competent Pichia GS115 cell.

Through detection via gel electrophoresis and sequencing, a fragment having identical size and sequence to the nucleotide sequence set forth in SEQ ID NO: 1 can be successfully amplified with the recombinant Pichia plasmid of the present invention, the amino acid sequence encoded therefrom is identical to the PprI protein of Deinococcus radiodurans with a relative molecular mass of 43 KD, as demonstrated by SDS-PAGE electrophoresis, Western blotting and mass spectrometry. Meanwhile, a band for PprI protein secretory expression can be detected 24 hours after inducing the expression from the recombinant engineered Pichia strain with methanol. Preferably, for induction of the protein expression at a methanol final concentration of is 1%, at a temperature of 30° C., pH 6.0, the protein of interest has the highest expression of 0.35 mg/ml at 120 h after induction. The result of the above detections shows that, the PprI protein can be successfully expressed and secreted in Pichia with the DNA molecule, recombinant Pichia plasmid and recombinant engineered Pichia strain provided in the present invention, which demonstrates that the DNA molecule is useful for the preparation of recombinant Pichia plasmids, recombinant engineered Pichia strains and medicament against radiation damages.

From the above-mentioned technical solutions, the sequence of the pprI gene of Deinococcus radiodurans is optimized and engineered, provided that the amino acid sequence of PprI protein keeps constant, to encode a new pprI gene, which allows successful construction of a recombinant Pichia plasmid and a recombinant engineered Pichia strain, as well as expression and secretion of the PprI protein, establishing a solid basis for further application of the yeast fermentation system to massively and efficiently prepare protein medication against radiation damage.

DESCRIPTION OF THE DRAWINGS

FIG. 1 shows a schematic diagram of Overlapping PCR amplification.

FIG. 2 shows a schematic diagram of construction of a recombinant Pichia plasmid.

FIG. 3 shows graphs of agarose gel electrophoresis of the DNA molecule, wherein lanes A-B are fragments 1 and 2; lanes C-J are fragment 3; lanes K-O are full-length Pi-pprI gene, with arrows indicating the size (bp) of bands for DNA molecular weight standards.

FIG. 4 shows a graph of agarose gel electrophoresis of the DNA molecule introduced with a 6× His tag sequence, wherein 1 is PCR amplification product, and M is Marker.

FIG. 5 shows a graph of agarose gel electrophoresis for PCR verification of the Escherichia coli recon Pi-pprI gene, wherein lane A is a negative control, i.e. no transformed Escherichia coli template was added; lanes B-L are the PCR products with transformed Escherichia coli as the template; lane N is the PCR product with Pi-pprI gene as the template (positive control).

FIG. 6 shows a graph of agarose gel electrophoresis for the plasmid DNA of the Escherichia coli recon, wherein lane 1 is pHBM905A plasmid (negative control), which plasmid has a stuffer fragment of 1200 bp in its multiple cloning site; lanes 2-12 are plasmids for single colonies corresponding to B-L in FIG. 5.

FIG. 7 shows pHBM-Pi-pprI and the Sal I restriction map thereof, wherein lane A is the recombinant plasmid pHBM-Pi-pprI and lanes B-D are Sal I restriction map of the recombinant plasmid pHBM-Pi-pprI.

FIG. 8 shows a graph of agarose gel electrophoresis for PCR verification of a pHBM-Pi-pprI Pichia transformant, wherein lane A is the PCR product with the pHBM905A plasmid as the template (negative control); lane 2 is the PCR product with the recombinant plasmid pHBM-Pi-pprI as the template (positive control); and lanes 3-16 are the PCR products with the pHBM-Pi-pprI Pichia transformant as the template.

FIG. 9 shows a SDS-PAGE image of the inducted expression of the PprI protein in the pHBM-Pi-pprI Pichia transformant, wherein the control lane is the culture supernatant of the pHBM905A Pichia transformant as the negative control; lanes 1-7 are culture supernatants of the pHBM-Pi-pprI Pichia transformant after induction for 1-7 days, respectively, with a loading amount of 30 μl (which corresponds to 24 μl of the culture supernatant) for each lane; lane M is Marker.

FIG. 10 shows Western Blot detection of the pHBM-Pi-pprI Pichia transformant, wherein 1 is the fermented supernatant of the first positive Pichia transformant with induction for 2 days; 2 is the fermented supernatant of the second positive Pichia transformant with induction for 2 days; 3 is the fermented supernatant of the first positive Pichia transformant with induction for 1 day; and lane M is Marker, with a loading amount of 16 μl of the culture supernatant for each lane.

FIG. 11 shows a peptide mass fingerprinting (PMF) of the pHBM-Pi-pprI Pichia transformant on Ultraflex II TOF/TOF mass spectrometer.

DETAILED EMBODIMENTS

The present invention discloses a DNA molecule as well as a recombinant Pichia plasmid and a recombinant Pichia strain efficiently expressing the PrpI protein of Deinococcus radiodurans. In view of the disclosure herein, these can be achieved by suitably improving process parameters for those skilled in the art. It is in particular to be noted that, all the similar substitutions or modifications are obvious for those skilled in the art, which will all be deemed to be included in the present invention. The DNA molecule, recombinant Pichia plasmid and recombinant Pichia strain of the present invention have been described with preferred examples, and related artisans can make modifications or suitable alterations and combinations to achieve and apply the technology of the present invention without departing from the content, spirit and scope of the present invention.

Test materials used in the examples are as follows:

1. Strains and Plasmids

Escherichia coli strain XL10-GOLD and Pichia pastoris strain GS115 were purchased from Invitrogen; Pichia expression vector pHBM-905A (8923 bp) was gifted by Professor M A Lixin from Hubei University (M A Lixin, ZHAO Xixuan, CHEN Wanping, L I Yexing, F U Ling, Y A O Yonglan. A METHOD FOR IN VITRO EFFICIENT CONSTRUCTION OF MULTI-COPY PICHIA EXPRESSION VECTOR. Patent Application No.: 201210591987.X), with a plasmid profile set forth in FIG. 2.

2. Reagents and Culture Media

Taq DNA polymerase, restriction endonuclease, T4 DNA ligase, etc. were all purchased from TaKaRa Biotechnology (Dalian) Co., Ltd. Plasmid DNA extraction kit and DNA fragment gel recovery kit were both purchased from Axygen Biotechnology (Hangzhou) Co., Ltd. DNA molecular weight standards were purchased from Beijing SBS Genetech Co., Ltd. Protein molecular weight standards were purchased from Bio-Rad Laboratories, Inc. Yeast nitrogen base (YNB) was purchased from DIFCO Corp. Mouse-derived anti-His tag antibody was a product from SIGMA Corporation. HRP-crosslinked rabbit anti-murine antibody was a product from Invitrogen Corporation. ECL chemiluminescence kit was purchased from Millipore Corporation. Other reagents were all chemically pure or analytically pure products made in China.

Escherichia coli culture medium: LB: 1% peptone, 0.5% yeast extract, 1% NaCl, pH 7.0.

Yeast culture medium: YPD plate (with each 100 ml double-distilled water solution containing 1 g of yeast extract, 2 g of peptone, 2 g of glucose and 2 g of agar powder), BMGY (with each 100 ml double-distilled water solution containing 1 g of yeast extract, 2 g of peptone, 1.34 g of TNB and 1 ml of glycerol), BMMY (with each 100 ml double-distilled water solution containing 1 g of yeast extract, 2 g of peptone, 2 g of glucose and 1 ml of methanol), were purchased from Shanghai root biological technology limited company.

The present invention will be further illustrated as follows, in conjunction with examples.

EXAMPLE 1

Optimization and Synthesis of the DNA Molecule of the Present Invention

In the present invention, the sequence of an Open Reading Frame (ORF) in the pprI gene (DR_0167, Gene ID: 1798483) of Deinococcus radiodurans R1 was optimized and modified to encode and synthesize a new pprI gene (Pi-pprI gene), i.e. the nucleotide sequence set forth in SEQ ID NO: 1, so as to efficiently express the protein of interest, provided that the amino acid sequence of PprI protein kept constant.

1. Synthetic Method

In the present invention, a series of overlapped primers of nucleotide sequences set forth in SEQ ID NOs: 2-41 were designed and synthesized in accordance with an artificially designed Pi-pprI gene, and then a DNA molecule comprising the nucleotide sequence set forth in SEQ ID NO: 1 and carrying a Cpo I restriction endonuclease site and a Not I restriction endonuclease site (so as to be convenient for subsequent construction of a recombinant plasmid) was synthesized and obtained by Overlapping PCR. The specific method is as follows:

By Overlapping PCR with the primers (p-1 to p-16, 404 bp) of the nucleotide sequences of SEQ ID NOs: 2-17, the primers (p-15 to p-28, 370 bp) of the nucleotide sequences of SEQ ID NOs: 16-29 and the primers (p-27 to p-40, 330 bp) of the nucleotide sequences of SEQ ID NOs: 28-41, respectively, three fragments were synthesized and obtained, which were fragment 1, fragment 2 and fragment 3 sequentially.

After synthesis of the three fragments, with these three fragments as templates, amplification was performed with the primer (p-1) of the nucleotide sequence of SEQ ID NO: 2 and the primer (p-40) of the nucleotide sequence of SEQ ID NO: 41, to form the entire DNA molecule.

From detection by agarose gel electrophoresis, the DNA molecule had a size in line with expectations, and the agarose gel electrophoretogram is shown in FIG. 3.

Wherein, the Overlapping PCR method was performed under the following synthesis conditions: 98° C. for 30 s, 58° C. for 30 s, 72° C. for 1 min, for totally 25 cycles; and finally 72° C. for 7 min. The reaction system (50 μl) was as follows:


p-1 (10 μmol/l)
1
μl
p-n (10 μmol/l)
1
μl
p-2 to p-(n − 1)(1 μmol/l)
each 1.5
μl
5 × PrimeSTAR ® Buffer
10
μl
dNTPs (2.5 mmol/l)
4
μl
PrimeSTAR ® HS DNA Polymerase
0.5
μl
ddH2O
added to a total volume of 50
μl

The PCR amplification was carried out under the following conditions: initial denaturation at 95° C. for 5 min; denaturation at 94° C. for 30 s, annealing at 50° C. for 30 s, extension at 72° C. for 90 s, for totally 30 cycles; and finally extension at 72° C. for 10 min, then kept at 4° C.

EXAMPLE 2

Synthesis of a DNA Molecule (Introduced with a 6× his Tag Sequence) of the Present Invention

With the DNA molecule obtained in Example 1 as the template, a PCR amplification was carried out with the primer of a nucleotide sequence of SEQ ID NO: 42 carrying a 6 × His tag sequence and a primer of a nucleotide sequence of SEQ ID NO: 41, to obtain a DNA molecule comprising a nucleotide sequence set forth in SEQ ID NO: 1 and a 6 × His tag sequence (carrying a Cpo I restriction endonuclease site and a Not I restriction endonuclease site). Wherein, the primer SEQ ID NO:42 was obtained by introduction of a 6 × His tag sequence based on the primer p-1.

The PCR amplification was carried out under the following conditions: initial denaturation at 95° C. for 5 min; denaturation at 94° C. for 30 s, annealing at 50° C. for 30 s, extension at 72° C. for 90 s, for totally 30 cycles; and finally extension at 72° C. for 10 min, then kept at 4° C.

3 μl of the PCR amplification product was detected by 0.8% agarose gel electrophoresis, and the results showed that the PCR amplification product has a size (1005 bp) in line with expectations, and the agarose gel electrophoretogram thereof is shown in FIG. 4.

EXAMPLE 3

Construction of a Recombinant Pichia Plasmid

A Pichia expression vector pHBM905A (8923 bp) was subjected to double digestions by Cop I and Not I enzymes, separated by agarose gel electrophoresis, and the large fragment (7719 bp) was recovered by cutting the gel.

The PCR product (1005 bp) synthesized in Example 2 was treated with T4 DNA polymerase in the presence of dTTP, and then ligated with the large fragment recovered by cutting the gel, to obtain a Pichia recombinant expression plasmid pHBM-905A-Pi-pprI (8706 bp), abbreviated as pHBM-Pi-pprI, and the construction process is shown in FIG. 2.

EXAMPLE 4

Identification of the Escherichia coli Transformant

In order to confirm whether the constructed recombinant Pichia plasmid was constructed successfully, it was transformed into Escherichia coli, and then identified.

1. Bacteria-Boiled PCR Identification

11 Transformant Colonies were Randomly Selected on the Escherichia Coli transformation plate, and separately transferred into 1.5 ml Eppendorf tubes containing 20 μl of sterile water, placed in a boiling water bath for 3 min and then cooled in an ice bath. After high speed centrifugation (14,000 rpm) for 1 min, 1-2 μl of the supernatant was taken to perform PCR amplification with primers p-1 and p-40. The PCR products were detected by agarose gel electrophoresis, set forth in FIG. 5. Results showed that, 10 of 11 transformants can give the genes synthesized in Example 2.

2. Agarose Gel Electrophoresis of the Plasmid DNA from the Transformant

The selected 11 transformant colonies were extracted for plasmid DNA with an AXYGEN plasmid MiniPrep kit, and subjected to detection with agarose gel electrophoresis, set forth in FIG. 6. Results showed that, 10 of 11 transformants are recombinant plasmids with the same size.

3. Sequencing Identification of the Plasmid DNA from the Transformant

Three recombinant plasmids, which were correct by colony PCR identification and plasmid size comparison, were randomly selected and were subjected to sequencing. Results showed that, the inserted pprI gene encoding sequence has a nucleotide sequence completely identical to that of the artificial synthesized SEQ ID NO: 1. The designed and synthesized Pi-pprI (the nucleotide sequence set forth in SEQ ID NO: 1) gene encoding sequence is completely different from the pprI gene encoding sequence (DR_0167, the nucleotide sequence set forth in SEQ ID NO: 43) from the original Deinococcus radiodurans R1.

4. Analysis Results of Bioinformatics Software

The Pi-pprI (the nucleotide sequence set forth in SEQ ID NO: 1) gene sequence was analyzed by using bioinformatics software (www.bio-soft.net/sms/index.html), and results showed that the amino acid sequence encoded therefrom is completely identical to that (an amino acid sequence set forth in SEQ ID NO: 44) of PprI protein (NP_293891.1) encoded from pprI gene of Deinococcus radiodurans R1.

Based on the above detection results, from Escherichia coli transformed with the recombinant Pichia plasmid, plasmids can be extracted, which have a correct band position and size, the sequencing result thereof is the same as that of the Pi-pprI (the nucleotide sequence set forth in SEQ ID NO: 1) gene sequence, and the Pi-pprI gene sequence can correctly express PprI protein, illustrating that the plasmid has been constructed successfully.

EXAMPLE 5

Establishment of a Recombinant Engineered Pichia Strain

The recombinant Pichia plasmid pHBM-Pi-pprI which was sequenced to be correct, was linearized with Sal I enzyme (with an agarose gel electrophoretogram set forth in FIG. 7), followed by electro-transformation into competent Pichia GS115 cells, to obtain a recombinant engineered Pichia strain (pHBM-Pi-pprI Pichia transformant). The preparation of the competent Pichia cells was performed in accordance with the operation manual of Invitrogen (see, www.pdffactory.com).

The electrotransformation experiment was carried out with the following related parameters: Voltage Booster: 4 kΩ, Capacitance: 50 μF, DC VOLTS: 410, Charge Rate: Fast.

The electrotransformed Pichia cells were coated onto a MD plate (MD: 1.34% YNB; 4×10-5% biotin, 2% glucose), then cultured at 28° C. for 2-3 days. The yeast transformant colonies on the MD plate were randomly selected and subjected to bacteria-boiled PCR identification. Primers used in the bacteria-boiled PCR were p-1 and p-40. PCR results showed that, in all the 14 Pichia transformants, the Pi-pprI (the nucleotide sequence set forth in SEQ ID NO: 1) gene sequence of 987 bp can be amplified (with the electrophoretogram set forth in FIG. 8), illustrating a successful transformation.

EXAMPLE 6

Induction Expression of PprI Protein from a Recombinant Engineered Pichia Strain (pHBM-Pi-pprI Pichia Transformant)

pHBM-Pi-pprI Pichia transformants which were identified to be positive, were selected and subjected to induction expression by shake-flask culture. A negative control strain was a transformant which was obtained by linearizing a empty vector plasmid pHBM-905A with Sal I enzyme followed by transformation into a Pichia GS115 strain. The method was as follows:

(1) A single colony of a pHBM-Pi-pprI Pichia transformant was selected, inoculated into 50 ml of BMGY liquid medium (charged at 10%, i.e., 50 ml of the medium charged into a 500 ml culture flask), cultured in a shaking incubator at 28-30° C. at a rotational speed of 250-300 rpm, and harvested until the strains grown to OD600=20-30.

(2) It was centrifuged at 5,000 rpm at room temperature for 5 min, removed the supernatant, and collected the cells, which were resuspended with 50 ml BMMY (BMMY: 2% peptone, 1% yeast extract, 1% ammonium sulfate, 0.34% YNB, 100 mmol/L PBS pH 6.0)

And then continued to be cultured in a shaking incubator at 28-30° C. at a rotational speed of 250-300 rpm.

(3) Methanol was added into the shaking flask until a final concentration of 1% every 24 h to achieve induction expression.

(4) 1 ml of culture solution was transferred into a 1.5 ml centrifuge tube at each of the following time points (24 h, 48 h, 72 h, 96 h, 120 h, 144 h, 168 h), and centrifuged at 5,000 rpm at room temperature for 5 min, and collected the supernatant which was stored in a 4° C. refrigerator for use.

(5) After all samples which were cultured for continuous 7 days have been collected, 40 ul of the culture supernatant taken from each sample at every time point was transferred into a new 1.5 ml Eppendorf tube respectively, each added with 10 ul of a treating solution for the protein sample (5×SDS-PAGE Loading buffer 100 ml: 1 mol/L Tris-HCl pH 6.8: 25 ml; glycerol: 50 ml; SDS: 10 g; bromophenol blue: 0.5 g; mercaptoethanol: 5.0 ml; double distilled water: metered to 100 ml), and after mixed uniformly, placed into a boiling water bath for denaturation for 10 min. For each sample, 30 ul was sampled to SDS-PAGE electrophoresis to observe the expression.

(6) Conditions for electrophoresis: spacer gel 4%, separation gel 12%, the electrophoresis buffer being Tris-Glycine Buffer (5×TGB 1 L: Tris base 15.1 g, Glycine 94 g, SDS 5 g, which were dissolved in 800 ml ddH2O, and then re-metered to 1 L), the staining solution being Coomassie Brilliant Blue, and destaining solution being 95% ethanol:glacial acetic acid:water=4.5:0.5:5(V:V:V).

Results showed that, a band of PprI protein secretory expression could be detected with induction for 24 h, and with the prolonging of the induction time, the amount of the PprI protein expression was also gradually increased, which reaches the highest when induction for 120 h, and then tends to be stable (with the electrophoretogram set forth in FIG. 9). In this figure, the PprI protein has a molecular weight of about 43 kD, suggesting that there may be glycosylated modification in this protein.

EXAMPLE 7

Western Blot Detection of the Expression Product from a Recombinant Engineered Pichia Strain (pHBM-Pi-pprI Pichia Transformant)

In order to judge whether the specifically expressed protein in the culture supernatant from the recombinant engineered Pichia strain (pHBM-Pi-pprI Pichia transformant) was indeed a 6× His-PprI fusion protein, in the present invention, 2 positive pHBM-Pi-pprI Pichia transformants were randomly selected therefrom and subjected to Western Blot detection with their methanol-induced culture supernatants, set forth in FIG. 10. Results showed that the anti-6× His tag antibody can specifically bind to the protein band adjacent to the position for 43 kDa in the culture supernatants of the 2 positive pHBM-Pi-pprI Pichia transformants, and the reaction intensity was correspondingly enhanced with the methanol induction time increasing, suggesting that the specific protein in the culture supernatants of the pHBM-Pi-pprI Pichia transformants was a 6× His-PprI fusion protein.

EXAMPLE 8

Mass Spectrum Identification of the Expression Product from a Recombinant Engineered Pichia Strain (pHBM-Pi-pprI Pichia Transformant)

In order to verify whether the protein in the supernatant from expression of the Pichia transformant was PprI protein of Deinococcus radiodurans, in the present invention, the protein band of interest which was separated by the gel for SDS-PAGE electrophoresis in Example 6 was cut, and detected for the Peptide Mass Fingerprinting (PMF) with Ultraflex II TOF/TOF mass spectrometer. The detection results were input into OMOSSA database of the National Center for Biotechnology Information (NCBI) for analysis.

The protein of interest was processed as follows:

1) The band of interest was cut with a gel-cutting pen and placed into a centrifuge tube.

2) It was washed with 50 μl of double distilled water twice, each for 10 min.

3) 50 μl of a destaining solution (50 mM NH4HCO3:CH3CN=1:1) was added for destaining at 37° C. for 20 min.

4) The step 3) was repeated until the blue color was taken off.

5) The gel strip was dehydrated with addition of 50 μl CH3CN until a white color, and dried under vacuum for 10 min.

6) 50 μl of 10 mM DTT (formulated with 25 mM NH4HCO3) was added and kept in 56° C. water bath for 1 h.

7) The sample was cooled to room temperature, removed the solution, and rapidly added with 50 μl of 30-40 mM IAA (formulated with 25 mM NH4HCO3) and placed into a dark room for 45 min.

8) The gel strip was washed successively with 25 mM NH4HCO3, 25 mM NH4HCO3+50% CH3CN twice, each for 10 min, and then dehydrated with CH3CN again until the gel strip became white, dried under vacuum for 10 min.

9) To each tube was added with 2-3 μl of 0.1 μg/μl Trypsin solution which has been diluted for 10-20 folds with 25 mM NH4HCO3, and after transient centrifugation, the solution was allowed to come into fully contact with the gel strip, kept at 4° C. for 30 min. After the zymolyte was absorbed completely, 25 mM NH4HCO3 was added to a total volume of 10-15 μl, and the resultant was kept overnight at 37° C.

10) The reaction was stopped with addition of 2 μl 0.1% TFA, which was mixed uniformly by shaking, centrifuged and collected the zymolyte for point targeting.

11) The molecular weight of the peptide fragments were detected by Peptide Mass Fingerprinting (PMF) analysis with Ultraflex II TOF/TOF mass spectrometer from Bruker Daltonics Corp. in USA to be in the range of 900-4000 (m/z, with z being one unit positive charge) (set forth in FIG. 11).

Search analysis on the PMF results resulted from the mass spectrometry was performed by logging in the NCBI nr database from the web of the US National Center for Biotechnology Information (www.ncbi.nlm.nih.gov) and selecting bacteria as the species. Results showed that this protein sequence is indeed a protein derived from Deinococcus radiodurans (NP_293891.1). It is suggested that the recombinant engineered Pichia strain containing a Pi-pprI gene sequence successfully expressed and secreted the PprI protein of Deinococcus radiodurans.

The foregoing description is only the preferred embodiments of the present invention, and it should be indicated that, for those ordinary skilled in the art, several improvements and modifications can also be made without departing from the principle of the present invention, which should be also deemed to be within the protection scope of the present invention.


SEQUENCE LISTING
<110> ZHANGJIAGANG INSTITUTE OF INDUSTRIAL TECHNOLOGIES,
SOOCHOW UNIVERSITY
<120> A DNA MOLECULE, RECOMBINANT PICHIA PLASMID AND
RECOMBINANT PICHIA STRAIN EFFICIENTLY EXPRESSING PPRI PROTEIN
OF DEINOCOCCUS RADIODURANS
<130>
10001.0016
<160>
   42
<170>
PatentIn version 3.3
<210>
    1
<211>
  987
<212>
DNA
<213>
Artificial Sequence
<220>
<223>
DNA sequence of Pi-pprI
<400>
    1
atgccatctg ctaacgtttc tccaccatgt ccaagtggtg ttagaggcgg tggcatgggt
60
cctaaagcta aggcagaggc ttctaagcca catcctcaga taccagtaaa gttgccattt
120
gttactgcac cagatgcttt ggccgctgct aaagccagaa tgcgtgattt ggctgccgct
180
tatgtagcag cattgccagg tagagatact cattctttga tggctggtgt gccaggagtt
240
gatttgaagt ttatgccatt gggttggagg gatggtgcat ttgatccaga acataacgta
300
attctgatta acagtgcagc tagacctgaa agacaaagat ttacattggc tcatgaaatc
360
ggacatgcta ttttgttggg tgatgatgat ttgttgtccg atattcatga tgcttacgaa
420
ggtgagagat tggaacaagt tattgaaact ttgtgtaatg ttgccgcagc agccatactg
480
atgccagaac cagttatagc cgaaatgttg gaaagattcg gtccaactgg tagagcattg
540
gcagaattgg ctaagagagc agaagttagt gcttcctctg ctttgtacgc tttgactgaa
600
caaacaccag tacctgttat ctacgctgtt tgtgctccag gtaagcctcc aagagaacaa
660
gcagcttccg acgaagatgc cggtccatct actgaaaagg ttttaactgt tagggcctct
720
tcttccacta gaggtgttaa gtacactctt gcttctggta ctccagttcc agctgatcat
780
cctgcagcct tggcattagc tacgggtatg gaagtcagag aagagtctta cgttccattt
840
agatctggta ggaaaatgaa ggctgaagtt gatgcatacc catctagagg aattgttgca
900
gtttctitig aatttgaccc agccagattg ggtagaaagg attctgagca ggctgataga
960
gatgaaccac aagatgctgc ccaataa
987
<210>
    2
<211>
   30
<212>
DNA
<213>
Artificial Sequence
<220>
<223>
DNA sequence of primer
<400>
    2
gtcagttcca tctgctaacg tttctccacc
30
<210>
    3
<211>
   46
<212>
DNA
<213>
Artificial Sequence
<220>
<223>
DNA sequence of primer
<400>
    3
cctctaacac cacttggaca tggtggagaa acgttagcag atggaa
46
<210>
    4
<211>
   46
<212>
DNA
<213>
Artificial Sequence
<220>
<223>
DNA sequence of primer
<400>
    4
atgtccaagt ggtgttagag gcggtggcat gggtcctaaa gctaag
46
<210>
    5
<211>
   46
<212>
DNA
<213>
Artificial Sequence
<220>
<223>
DNA sequence of primer
<400>
    5
tgaggatgtg gcttagaagc ctctgcctta gctttaggac ccatgc
46
<210>
    6
<211>
   46
<212>
DNA
<213>
Artificial Sequence
<220>
<223>
DNA sequence of primer
<400>
    6
gcttctaagc cacatcctca gataccagta aagttgccat ttgtta
46
<210>
    7
<211>
   46
<212>
DNA
<213>
Artificial Sequence
<220>
<223>
DNA sequence of primer
<400>
    7
agcggccaaa gcatctggtg cagtaacaaa tggcaacttt actggt
46
<210>
    8
<211>
   46
<212>
DNA
<213>
Artificial Sequence
<220>
<223>
DNA sequence of primer
<400>
    8
cagatgcttt ggccgctgct aaagccagaa tgcgtgattt ggctgc
46
<210>
    9
<211>
   46
<212>
DNA
<213>
Artificial Sequence
<220>
<223>
DNA sequence of primer
<400>
    9
tctacctggc aatgctgcta cataagcggc agccaaatca cgcatt
46
<210>
   10
<211>
   46
<212>
DNA
<213>
Artificial Sequence
<220>
<223>
DNA sequence of primer
<400>
   10
gcagcattgc caggtagaga tactcattct ttgatggctg gtgtgc
46
<210>
   11
<211>
   46
<212>
DNA
<213>
Artificial Sequence
<220>
<223>
DNA sequence of primer
<400>
   11
aatggcataa acttcaaatc aactcctggc acaccagcca tcaaag
46
<210>
   12
<211>
   46
<212>
DNA
<213>
Artificial Sequence
<220>
<223>
DNA sequence of primer
<400>
   12
agttgatttg aagtttatgc cattgggttg gagggatggt gcattt
46
<210>
   13
<211>
   46
<212>
DNA
<213>
Artificial Sequence
<220>
<223>
DNA sequence of primer
<400>
   13
aatcagaatt acgttatgtt ctggatcaaa tgcaccatcc ctccaa
46
<210>
   14
<211>
   46
<212>
DNA
<213>
Artificial Sequence
<220>
<223>
DNA sequence of primer
<400>
   14
tccagaacat aacgtaattc tgattaacag tgcagctaga cctgaa
46
<210>
   15
<211>
   46
<212>
DNA
<213>
Artificial Sequence
<220>
<223>
DNA sequence of primer
<400>
   15
ttcatgagcc aatgtaaatc tttgtctttc aggtctagct gcactg
46
<210>
   16
<211>
   46
<212>
DNA
<213>
Artificial Sequence
<220>
<223>
DNA sequence of primer
<400>
   16
caaagattta cattggctca tgaaatcgga catgctattt tgttgg
46
<210>
   17
<211>
   46
<212>
DNA
<213>
Artificial Sequence
<220>
<223>
DNA sequence of primer
<400>
   17
atatcggaca acaaatcatc atcacccaac aaaatagcat gtccga
46
<210>
   18
<211>
   46
<212>
DNA
<213>
Artificial Sequence
<220>
<223>
DNA sequence of primer
<400>
   18
gtgatgatga tttgttgtcc gatattcatg atgcttacga aggtga
46
<210>
   19
<211>
   46
<212>
DNA
<213>
Artificial Sequence
<220>
<223>
DNA sequence of primer
<400>
   19
agtttcaata acttgttcca atctctcacc ttcgtaagca tcatga
46
<210>
   20
<211>
   46
<212>
DNA
<213>
Artificial Sequence
<220>
<223>
DNA sequence of primer
<400>
   20
gagattggaa caagttattg aaactttgtg taatgttgcc gcagca
46
<210>
   21
<211>
   46
<212>
DNA
<213>
Artificial Sequence
<220>
<223>
DNA sequence of primer
<400>
   21
ctataactgg ttctggcatc agtatggctg ctgcggcaac attaca
46
<210>
   22
<211>
   46
<212>
DNA
<213>
Artificial Sequence
<220>
<223>
DNA sequence of primer
<400>
   22
ctgatgccag aaccagttat agccgaaatg ttggaaagat tcggtc
46
<210>
   23
<211>
   46
<212>
DNA
<213>
Artificial Sequence
<220>
<223>
DNA sequence of primer
<400>
   23
attctgccaa tgctctacca gttggaccga atctttccaa catttc
46
<210>
   24
<211>
   46
<212>
DNA
<213>
Artificial Sequence
<220>
<223>
DNA sequence of primer
<400>
   24
tggtagagca ttggcagaat tggctaagag agcagaagtt agtgct
46
<210>
   25
<211>
   46
<212>
DNA
<213>
Artificial Sequence
<220>
<223>
DNA sequence of primer
<400>
   25
cagtcaaagc gtacaaagca gaggaagcac taacttctgc tctctt
46
<210>
   26
<211>
   46
<212>
DNA
<213>
Artificial Sequence
<220>
<223>
DNA sequence of primer
<400>
   26
tgctttgtac gctttgactg aacaaacacc agtacctgtt atctac
46
<210>
   27
<211>
   46
<212>
DNA
<213>
Artificial Sequence
<220>
<223>
DNA sequence of primer
<400>
   27
ggcttacctg gagcacaaac agcgtagata acaggtactg gtgttt
46
<210>
   28
<211>
   46
<212>
DNA
<213>
Artificial Sequence
<220>
<223>
DNA sequence of primer
<400>
   28
ttgtgctcca ggtaagcctc caagagaaca agcagcttcc gacgaa
46
<210>
   29
<211>
   46
<212>
DNA
<213>
Artificial Sequence
<220>
<223>
DNA sequence of primer
<400>
   29
aaaccttttc agtagatgga ccggcatctt cgtcggaagc tgcttg
46
<210>
   30
<211>
   46
<212>
DNA
<213>
Artificial Sequence
<220>
<223>
DNA sequence of primer
<400>
   30
ggtccatcta ctgaaaaggt tttaactgtt agggcctctt cttcca
46
<210>
   31
<211>
   46
<212>
DNA
<213>
Artificial Sequence
<220>
<223>
DNA sequence of primer
<400>
   31
aagcaagagt gtacttaaca cctctagtgg aagaagaggc cctaac
46
<210>
   32
<211>
   46
<212>
DNA
<213>
Artificial Sequence
<220>
<223>
DNA sequence of primer
<400>
   32
ggtgttaagt acactcttgc ttctggtact ccagttccag ctgatc
46
<210>
   33
<211>
   46
<212>
DNA
<213>
Artificial Sequence
<220>
<223>
DNA sequence of primer
<400>
   33
cgtagctaat gccaaggctg caggatgatc agctggaact ggagta
46
<210>
   34
<211>
   46
<212>
DNA
<213>
Artificial Sequence
<220>
<223>
DNA sequence of primer
<400>
   34
agccttggca ttagctacgg gtatggaagt cagagaagag tcttac
46
<210>
   35
<211>
   46
<212>
DNA
<213>
Artificial Sequence
<220>
<223>
DNA sequence of primer
<400>
   35
ttcctaccag atctaaatgg aacgtaagac tcttctctga cttcca
46
<210>
   36
<211>
   46
<212>
DNA
<213>
Artificial Sequence
<220>
<223>
DNA sequence of primer
<400>
   36
gttccattta gatctggtag gaaaatgaag gctgaagttg atgcat
46
<210>
   37
<211>
   46
<212>
DNA
<213>
Artificial Sequence
<220>
<223>
DNA sequence of primer
<400>
   37
aactgcaaca attcctctag atgggtatgc atcaacttca gccttc
46
<210>
   38
<211>
   46
<212>
DNA
<213>
Artificial Sequence
<220>
<223>
DNA sequence of primer
<400>
   38
catctagagg aattgttgca gtttcttttg aatttgaccc agccag
46
<210>
   39
<211>
   46
<212>
DNA
<213>
Artificial Sequence
<220>
<223>
DNA sequence of primer
<400>
   39
ctgctcagaa tcctttctac ccaatctggc tgggtcaaat tcaaaa
46
<210>
   40
<211>
   46
<212>
DNA
<213>
Artificial Sequence
<220>
<223>
DNA sequence of primer
<400>
   40
ggtagaaagg attctgagca ggctgataga gatgaaccac aagatg
46
<210>
   41
<211>
   30
<212>
DNA
<213>
Artificial Sequence
<220>
<223>
DNA sequence of primer
<400>
   41
ggccattatt gggcagcatc ttgtggttca
30
<210>
   42
<211>
   47
<212>
DNA
<213>
Artificial Sequence
<220>
<223>
DNA sequence of primer
<400>
   42
gtcacatcat caccaccatc atgttccatc tgctaacgtt tctccac
47

<160> NUMBER OF SEQ ID NOS: 42

<210> SEQ ID NO: 1

<211> LENGTH: 987

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: DNA sequence of Pi-pprI

<400> SEQENCE: 1

atgccatctg ctaacgtttc tccaccatgt ccaagtggtg ttagaggcgg tggcatgggt 60

cctaaagcta aggcagaggc ttctaagcca catcctcaga taccagtaaa gttgccattt 120

gttactgcac cagatgcttt ggccgctgct aaagccagaa tgcgtgattt ggctgccgct 180

tatgtagcag cattgccagg tagagatact cattctttga tggctggtgt gccaggagtt 240

gatttgaagt ttatgccatt gggttggagg gatggtgcat ttgatccaga acataacgta 300

attctgatta acagtgcagc tagacctgaa agacaaagat ttacattggc tcatgaaatc 360

ggacatgcta ttttgttggg tgatgatgat ttgttgtccg atattcatga tgcttacgaa 420

ggtgagagat tggaacaagt tattgaaact ttgtgtaatg ttgccgcagc agccatactg 480

atgccagaac cagttatagc cgaaatgttg gaaagattcg gtccaactgg tagagcattg 540

gcagaattgg ctaagagagc agaagttagt gcttcctctg ctttgtacgc tttgactgaa 600

caaacaccag tacctgttat ctacgctgtt tgtgctccag gtaagcctcc aagagaacaa 660

gcagcttccg acgaagatgc cggtccatct actgaaaagg ttttaactgt tagggcctct 720

tcttccacta gaggtgttaa gtacactctt gcttctggta ctccagttcc agctgatcat 780

cctgcagcct tggcattagc tacgggtatg gaagtcagag aagagtctta cgttccattt 840

agatctggta ggaaaatgaa ggctgaagtt gatgcatacc catctagagg aattgttgca 900

gtttcttttg aatttgaccc agccagattg ggtagaaagg attctgagca ggctgataga 960

gatgaaccac aagatgctgc ccaataa 987

<210> SEQ ID NO: 2

<211> LENGTH: 30

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: DNA sequence of primer

<400> SEQENCE: 2

gtcagttcca tctgctaacg tttctccacc 30

<210> SEQ ID NO: 3

<211> LENGTH: 46

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: DNA sequence of primer

<400> SEQENCE: 3

cctctaacac cacttggaca tggtggagaa acgttagcag atggaa 46

<210> SEQ ID NO: 4

<211> LENGTH: 46

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: DNA sequence of primer

<400> SEQENCE: 4

atgtccaagt ggtgttagag gcggtggcat gggtcctaaa gctaag 46

<210> SEQ ID NO: 5

<211> LENGTH: 46

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: DNA sequence of primer

<400> SEQENCE: 5

tgaggatgtg gcttagaagc ctctgcctta gctttaggac ccatgc 46

<210> SEQ ID NO: 6

<211> LENGTH: 46

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: DNA sequence of

<400> SEQENCE: 6

gcttctaagc cacatcctca gataccagta aagttgccat ttgtta 46

<210> SEQ ID NO: 7

<211> LENGTH: 46

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: DNA sequence of primer

<400> SEQENCE: 7

agcggccaaa gcatctggtg cagtaacaaa tggcaacttt actggt 46

<210> SEQ ID NO: 8

<211> LENGTH: 46

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: DNA sequence of primer

<400> SEQENCE: 8

cagatgcttt ggccgctgct aaagccagaa tgcgtgattt ggctgc 46

<210> SEQ ID NO: 9

<211> LENGTH: 46

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: DNA sequence of primer

<400> SEQENCE: 9

tctacctggc aatgctgcta cataagcggc agccaaatca cgcatt 46

<210> SEQ ID NO: 10

<211> LENGTH: 46

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: DNA sequence of primer

<400> SEQENCE: 10

gcagcattgc caggtagaga tactcattct ttgatggctg gtgtgc 46

<210> SEQ ID NO: 11

<211> LENGTH: 46

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: DNA sequence of

<400> SEQENCE: 11

aatggcataa acttcaaatc aactcctggc acaccagcca tcaaag 46

<210> SEQ ID NO: 12

<211> LENGTH: 46

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: DNA sequence of primer

<400> SEQENCE: 12

agttgatttg aagtttatgc cattgggttg gagggatggt gcattt 46

<210> SEQ ID NO: 13

<211> LENGTH: 46

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: DNA sequence of primer

<400> SEQENCE: 13

aatcagaatt acgttatgtt ctggatcaaa tgcaccatcc ctccaa 46

<210> SEQ ID NO: 14

<211> LENGTH: 46

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: DNA sequence of primer

<400> SEQENCE: 14

tccagaacat aacgtaattc tgattaacag tgcagctaga cctgaa 46

<210> SEQ ID NO: 15

<211> LENGTH: 46

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: DNA sequence of primer

<400> SEQENCE: 15

ttcatgagcc aatgtaaatc tttgtctttc aggtctagct gcactg 46

<210> SEQ ID NO: 16

<211> LENGTH: 46

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: DNA sequence of primer

<400> SEQENCE: 16

caaagattta cattggctca tgaaatcgga catgctattt tgttgg 46

<210> SEQ ID NO: 17

<211> LENGTH: 46

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: DNA sequence of

<400> SEQENCE: 17

atatcggaca acaaatcatc atcacccaac aaaatagcat gtccga 46

<210> SEQ ID NO: 18

<211> LENGTH: 46

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: DNA sequence of primer

<400> SEQENCE: 18

gtgatgatga tttgttgtcc gatattcatg atgcttacga aggtga 46

<210> SEQ ID NO: 19

<211> LENGTH: 46

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: DNA sequence of primer

<400> SEQENCE: 19

agtttcaata acttgttcca atctctcacc ttcgtaagca tcatga 46

<210> SEQ ID NO: 20

<211> LENGTH: 46

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: DNA sequence of primer

<400> SEQENCE: 20

gagattggaa caagttattg aaactttgtg taatgttgcc gcagca 46

<210> SEQ ID NO: 21

<211> LENGTH: 46

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: DNA sequence of

<400> SEQENCE: 21

ctataactgg ttctggcatc agtatggctg ctgcggcaac attaca 46

<210> SEQ ID NO: 22

<211> LENGTH: 46

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: DNA sequence of primer

<400> SEQENCE: 22

ctgatgccag aaccagttat agccgaaatg ttggaaagat tcggtc 46

<210> SEQ ID NO: 23

<211> LENGTH: 46

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: DNA sequence of

<400> SEQENCE: 23

attctgccaa tgctctacca gttggaccga atctttccaa catttc 46

<210> SEQ ID NO: 24

<211> LENGTH: 46

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: DNA sequence of primer

<400> SEQENCE: 24

tggtagagca ttggcagaat tggctaagag agcagaagtt agtgct 46

<210> SEQ ID NO: 25

<211> LENGTH: 46

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: DNA sequence of primer

<400> SEQENCE: 25

cagtcaaagc gtacaaagca gaggaagcac taacttctgc tctctt 46

<210> SEQ ID NO: 26

<211> LENGTH: 46

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: DNA sequence of primer

<400> SEQENCE: 26

tgctttgtac gctttgactg aacaaacacc agtacctgtt atctac 46

<210> SEQ ID NO: 27

<211> LENGTH: 46

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: DNA sequence of primer

<400> SEQENCE: 27

ggcttacctg gagcacaaac agcgtagata acaggtactg gtgttt 46

<210> SEQ ID NO: 28

<211> LENGTH: 46

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: DNA sequence of primer

<400> SEQENCE: 28

ttgtgctcca ggtaagcctc caagagaaca agcagcttcc gacgaa 46

<210> SEQ ID NO: 29

<211> LENGTH: 46

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: DNA sequence of primer

<400> SEQENCE: 29

aaaccttttc agtagatgga ccggcatctt cgtcggaagc tgcttg 46

<210> SEQ ID NO: 30

<211> LENGTH: 46

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: DNA sequence of primer

<400> SEQENCE: 30

ggtccatcta ctgaaaaggt tttaactgtt agggcctctt cttcca 46

<210> SEQ ID NO: 31

<211> LENGTH: 46

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: DNA sequence of primer

<400> SEQENCE: 31

aagcaagagt gtacttaaca cctctagtgg aagaagaggc cctaac 46

<210> SEQ ID NO: 32

<211> LENGTH: 46

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: DNA sequence of primer

<400> SEQENCE: 32

ggtgttaagt acactcttgc ttctggtact ccagttccag ctgatc 46

<210> SEQ ID NO: 33

<211> LENGTH: 46

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: DNA sequence of primer

<400> SEQENCE: 33

cgtagctaat gccaaggctg caggatgatc agctggaact ggagta 46

<210> SEQ ID NO: 34

<211> LENGTH: 46

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: DNA sequence of primer

<400> SEQENCE: 34

agccttggca ttagctacgg gtatggaagt cagagaagag tcttac 46

<210> SEQ ID NO: 35

<211> LENGTH: 46

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: DNA sequence of primer

<400> SEQENCE: 35

ttcctaccag atctaaatgg aacgtaagac tcttctctga cttcca 46

<210> SEQ ID NO: 36

<211> LENGTH: 46

<212> TYPE: DNA

<213> ORGANISM: Artificially synthesized

<220> FEATURE:

<223> OTHER INFORMATION: DNA sequence of primer

<400> SEQENCE: 36

gttccattta gatctggtag gaaaatgaag gctgaagttg atgcat 46

<210> SEQ ID NO: 37

<211> LENGTH: 46

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: DNA sequence of primer

<400> SEQENCE: 37

aactgcaaca attcctctag atgggtatgc atcaacttca gccttc 46

<210> SEQ ID NO: 38

<211> LENGTH: 46

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: DNA sequence of primer

<400> SEQENCE: 38

catctagagg aattgttgca gtttcttttg aatttgaccc agccag 46

<210> SEQ ID NO: 39

<211> LENGTH: 46

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: DNA sequence of primer

<400> SEQENCE: 39

ctgctcagaa tcctttctac ccaatctggc tgggtcaaat tcaaaa 46

<210> SEQ ID NO: 40

<211> LENGTH: 46

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: DNA sequence of primer

<400> SEQENCE: 40

ggtagaaagg attctgagca ggctgataga gatgaaccac aagatg 46

<210> SEQ ID NO: 41

<211> LENGTH: 30

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: DNA sequence of primer

<400> SEQENCE: 41

ggccattatt gggcagcatc ttgtggttca 30

<210> SEQ ID NO: 42

<211> LENGTH: 47

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: DNA sequence of primer

<400> SEQENCE: 42

gtcacatcat caccaccatc atgttccatc tgctaacgtt tctccac 47

Read more
PatSnap Solutions

Great research starts with great data.

Use the most comprehensive innovation intelligence platform to maximise ROI on research.

Learn More

Patent Valuation

$

Reveal the value <>

25.0/100 Score

Market Attractiveness

It shows from an IP point of view how many competitors are active and innovations are made in the different technical fields of the company. On a company level, the market attractiveness is often also an indicator of how diversified a company is. Here we look into the commercial relevance of the market.

27.0/100 Score

Market Coverage

It shows the sizes of the market that is covered with the IP and in how many countries the IP guarantees protection. It reflects a market size that is potentially addressable with the invented technology/formulation with a legal protection which also includes a freedom to operate. Here we look into the size of the impacted market.

74.0/100 Score

Technology Quality

It shows the degree of innovation that can be derived from a company’s IP. Here we look into ease of detection, ability to design around and significance of the patented feature to the product/service.

40.0/100 Score

Assignee Score

It takes the R&D behavior of the company itself into account that results in IP. During the invention phase, larger companies are considered to assign a higher R&D budget on a certain technology field, these companies have a better influence on their market, on what is marketable and what might lead to a standard.

21.0/100 Score

Legal Score

It shows the legal strength of IP in terms of its degree of protecting effect. Here we look into claim scope, claim breadth, claim quality, stability and priority.

Citation

Patents Cited in This Cited by
Title Current Assignee Application Date Publication Date
Methods and composition to enhance production of fully functional p-glycoprotein in pichia pastoris TEXAS TECH UNIVERSITY SYSTEM 30 June 2012 10 January 2013
一种耐辐射球菌抗逆相关基因及其应用 浙江大学 30 April 2009 17 March 2010
一种含有原核基因pprI的真核重组质粒及其用途 苏州大学 07 January 2009 29 July 2009
一种离体高效构建多拷贝毕赤酵母表达载体的方法 湖北大学,湖北花果山实业有限公司 29 December 2012 05 February 2014
RECOMBINANT EUKARYOTIC EXPRESSION PLASMID ENCODING pprI GENE OF DEINOCOCCUS RADIODURANS R1 AND ITS FUNCTIONS SOOCHOW UNIVERSITY 24 March 2010 29 September 2011
See full citation <>

More Patents & Intellectual Property

PatSnap Solutions

PatSnap solutions are used by R&D teams, legal and IP professionals, those in business intelligence and strategic planning roles and by research staff at academic institutions globally.

PatSnap Solutions
Search & Analyze
The widest range of IP search tools makes getting the right answers and asking the right questions easier than ever. One click analysis extracts meaningful information on competitors and technology trends from IP data.
Business Intelligence
Gain powerful insights into future technology changes, market shifts and competitor strategies.
Workflow
Manage IP-related processes across multiple teams and departments with integrated collaboration and workflow tools.
Contact Sales
Clsoe
US10000761 DNA molecule used recombinant 1 US10000761 DNA molecule used recombinant 2 US10000761 DNA molecule used recombinant 3